MYD88 and Alzheimer disease: In this context, we have investigated if the AD-specific treatment with Rivastigmine, an acetylcholinesterase inhibitor, having also anti-inflammatory properties [33], is impacting on MYD88 transcript levels in the blood of the investigated AT mice.